Citigroup Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price objective cut by analysts at Citigroup from $305.00 to $285.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the conglomerate’s stock. Citigroup’s price objective points to a potential upside of 19.25% from the stock’s previous close.

Several other brokerages have also issued reports on DHR. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Evercore ISI upped their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. TD Cowen raised their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, Guggenheim assumed coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Trading Up 0.3 %

DHR stock opened at $239.00 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a market cap of $172.62 billion, a P/E ratio of 45.61, a PEG ratio of 4.33 and a beta of 0.83. The business has a fifty day moving average of $236.17 and a 200-day moving average of $254.11.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 EPS. The firm’s revenue was up 3.1% on a year-over-year basis. As a group, equities research analysts expect that Danaher will post 7.5 EPS for the current year.

Institutional Investors Weigh In On Danaher

A number of large investors have recently added to or reduced their stakes in DHR. Benjamin Edwards Inc. lifted its holdings in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC raised its stake in Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Certified Advisory Corp raised its stake in Danaher by 4.5% in the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares in the last quarter. Meridian Financial Partners LLC grew its position in shares of Danaher by 4.4% during the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. increased its holdings in shares of Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.